Its goal is to encourage smoother digestion, better bowel regularity, and enhanced metabolic support without harsh chemical stimulants or risky additives
("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce continued progress in its sublingual Semaglutide oral dissolvable film ("ODF") program, marking the next stage of development for the Company's GLP-1 delivery platform
Thanks to their anti-inflammatory action through different mechanisms, GLP1-RA may provide, in a selected cohort of patients, the cardiovascular protection desired with targeted therapies, but without the wide side-effects of those drugs
Select Size / Specification Selected: 5mg x 10vials Choose Pack Size Quantity Research Use Only All products are intended strictly for laboratory research purposes and are not for human consumption
However, when taken in combination with other medications that can lower blood sugar (like sulfonylureas or insulin), there may be an increased risk of hypoglycemia